Skip to navigation Skip to content

Non-small cell lung cancer (NSCLC) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051128

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised crizotinib, and entrectinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

NSCLC and listing dates

NSCLC is one of the major types of lung cancer that can affect smokers and non-smokers.

Listing dates:

  • crizotinib - 1 July 2015
  • entrectinib - 1 August 2020

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs